Pediatric Solid Tumor Clinical Trial
Official title:
Multicenter Cohort Study To Evaluate Outcomes After Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults With Solid Tumors: The iCat2, GAIN Consortium Study
Verified date | January 2024 |
Source | Dana-Farber Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.
Status | Active, not recruiting |
Enrollment | 825 |
Est. completion date | October 2025 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 30 Years |
Eligibility | Inclusion Criteria: - Age -- Age = 30 years at time of initial qualifying solid tumor diagnosis - Diagnosis -- Histologic diagnosis of solid malignancy (excluding brain tumors and lymphoma) that meets at least one of the following criteria: - Refractory, defined as tumor progression after initiation of standard first line therapy without having achieved a prior partial or complete remission OR Biopsy proven residual disease at the completion of planned standard initial front-line therapy. - Recurrent, defined as tumor progression after achieving a prior partial or complete remission - Newly diagnosed high risk disease, defined as having an expected event free survival of < 50% at 2 years. - Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group). - Examples include (eligibility not limited to these examples): - Histology typically associated with a fusion in which fusion is not detected. - Ewing-like sarcoma - Undifferentiated sarcoma - Inflammatory myofibroblastic tumor without ALK fusion - Infantile fibrosarcoma without NTRK fusion - Specimen Samples - Sufficient tumor specimen available to meet the minimum requirements for profiling from diagnosis or progression / recurrence --- OR - Surgery / biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; OR - Patient has already had molecular profiling and patient has not yet started matched targeted therapy based on the report . Exclusion Criteria: - No Therapy Planned -- Patients who have declined further anticancer therapy will be excluded. - Performance Status -- Patients with Lansky (age < 16 years) or Karnofsky (age =16 years) score < 50 will be excluded. - Life Expectancy -- Patients with anticipated life expectancy < 3 months will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | University of Chicago Comer Children's Hospital | Chicago | Illinois |
United States | Nationwide Children's Hospital | Columbus | Ohio |
United States | University of Texas Southwestern Medical Center at Dallas | Dallas | Texas |
United States | Columbia University Medical Center | New York | New York |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | University of Utah Childrens Medical Center | Salt Lake City | Utah |
United States | University of California San Francisco | San Francisco | California |
United States | Seattle Children's Hospital | Seattle | Washington |
United States | Children's National Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival | In pediatric patients with recurrent or refractory solid tumors who undergo successful molecular profiling, a) to describe the overall survival of patients by treatment group (iCatM, iCatUM and UM); b) to identify demographic, clinical, and genomic factors associated with overall survival from the time of relapse/progression (OSr); and c)to store tumor material, derived cell lines / xenografts, and blood samples for general sample banking and potential future research. | 18 months | |
Secondary | Identification of the patient, clinical, and medication access factors associated with a) having an iCat recommendation and b) with receipt of matched targeted therapy. | 2 Years | ||
Secondary | Determination of factors associated with response and progression-free survival time by treatment group for patients with recurrent/refractory disease and measurable/evaluable disease. | 2 Years | ||
Secondary | Description of the frequency and range of molecular alterations in pediatric solid tumors at diagnosis and at relapse including a comparison of potentially targetable variants in paired tumor samples obtained from relapse and at initial diagnosis. | 2 Years | ||
Secondary | Determination of whether participation in a genomics study provides psychological well-being and whether that is associated with level of genomic comprehension and with receipt of an iCat recommendation. | 2 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05151718 -
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
|
||
Recruiting |
NCT02787876 -
Pegteograstim in Children With Solid Tumors
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05620862 -
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04944875 -
Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging.
|
N/A | |
Recruiting |
NCT03618381 -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Recruiting |
NCT04897321 -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
|
Phase 1 | |
Completed |
NCT05024331 -
A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor
|
||
Active, not recruiting |
NCT04483778 -
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT04239040 -
GVAX Plus Checkpoint Blockade in Neuroblastoma
|
Phase 1 | |
Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
Recruiting |
NCT02339753 -
Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT03222258 -
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
|
||
Completed |
NCT02564198 -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03273829 -
Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumors and Leukemias
|
Phase 1 | |
Completed |
NCT03455140 -
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
|
Phase 1/Phase 2 | |
Completed |
NCT01853345 -
iCAT for Recurrent/Refractory/HR Solid Tumors
|
N/A | |
Active, not recruiting |
NCT03478462 -
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
|
Phase 1 | |
Not yet recruiting |
NCT05322187 -
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
|
Phase 2/Phase 3 |